Cencora Inc (COR)

Abbott Laboratories ABT recently made its FreeStyle Libre 3 Plus sensor available to Canadians living with diabetes. This latest generation glucose monitoring device features the world's smallest glucose...

Boston Scientific’s BSX robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the WATCHMAN...

Alcon Inc.’s ALC UNITY Vitreoretinal Cataract System (“VCS”) has recently received approval from Health Canada. UNITY VCS is the latest innovation from the Alcon Vision Suite — a portfolio of innovative...

Cencora is scheduled to release its second-quarter results next month, with analysts projecting double-digit earnings growth.

Alcon’s ALC Vision Care business continues to gain from its diverse portfolio of contact lenses and ocular health products. Additionally, the introduction of new products is poised to help it grow in...

Abbott Laboratories ABT recently received Health Canada approval for the i-STAT TBI test cartridge for use with whole blood. It is designed to help clinicians assess suspected concussion at the patient's...

Cardinal Health has outperformed its healthcare service peers over the past year, with analysts maintaining a positive outlook on its continued growth trajectory.

Due to Cencora’s strong performance relative to the broader Dow over the past year, Wall Street analysts remain bullish about the stock’s prospects.

McKesson has significantly outpaced the broader healthcare sector over the past year, and analysts remain strongly bullish on the stock’s prospects.

McKesson’s MCK shares have gained 4.4% following its fourth-quarter fiscal 2025 earnings release on May 9. The post-earnings upside reflects growing investor confidence in McKesson’s strategic execution...